Dexrazoxane Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI), 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI), ADR 529, ADR-529, ADR529 +7 more

Pipeline

Phase 1: 1Phase 3: 2

Top Sponsors

Stichting Hemato-Oncologie voor Volwassenen Nederland1
Children's Oncology Group1
Andrew E. Place, MD1

Indications

Cancer3
Acute Leukemia of Ambiguous Lineage in Relapse1
Lymphoblastic Lymphoma, Refractory1
Lymphoblastic Lymphoma, in Relapse1
Treatment-Related Acute Myeloid Leukemia1

Other1 trial

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Phase 3

Birmingham, Alabama1 trial

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Hospital of Alabama

Phase 3

San Francisco, California1 trial

Venetoclax Basket Trial for High Risk Hematologic Malignancies

University of California San Francisco-Benioff Children's Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.